Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.

MLA

Oudard, Stéphane, et al. “Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.” JAMA Oncology, vol. 9, no. 12, Dec. 2023, pp. 1629–38. EBSCOhost, https://doi.org/10.1001/jamaoncol.2023.4255.

APA

Oudard, S., Ratta, R., Voog, E., Barthelemy, P., Thiery-Vuillemin, A., Bennamoun, M., Hasbini, A., Aldabbagh, K., Saldana, C., Sevin, E., Amela, E., Von Amsberg, G., Houede, N., Besson, D., Feyerabend, S., Boegemann, M., Pfister, D., Schostak, M., Huillard, O., … Helissey, C. (2023). Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. JAMA Oncology, 9(12), 1629–1638. https://doi.org/10.1001/jamaoncol.2023.4255

Chicago

Oudard, Stéphane, Raffaele Ratta, Eric Voog, Philippe Barthelemy, Antoine Thiery-Vuillemin, Mostefa Bennamoun, Ali Hasbini, et al. 2023. “Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.” JAMA Oncology 9 (12): 1629–38. doi:10.1001/jamaoncol.2023.4255.